^
    Back
    Association details:
    Biomarker:WNK1-ROS1 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib

    Excerpt:
    The patient achieved a partial response after treatment with crizotinib….We identified a novel WNK1-ROS1 fusion that was sensitive to crizotinib and developed an ROS1 G2032R mutation when the disease progressed.
    DOI:
    10.1016/j.lungcan.2018.12.011